In these two studies, a PC cell vaccine induced a CD8+ T cell response, specific to mesothelin, regardless of HLA match between the tumor vaccine and recipient—demonstrating that cross-priming had occurred [80, 82]. This evidence concerns the gene CD8A and neoplasm.